Sarepta Therapeutics, Inc. (SRPT) Q1 2018 Earnings Results

Sarepta Therapeutics Misses on EPS — Stock Down 0.31%

Sarepta Therapeutics reported a loss per share of $-0.28, which was below expectations, although no revenue figures were disclosed. The stock reacted negatively, declining by 0.31%. The lack of guidance and focus on pipeline advancement suggests uncertainty in the near term, which may have influenced investor sentiment.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.28	N/A	-0.28%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing their commitment to ongoing projects. They did not provide specific future guidance.

Management did not provide specific guidance for the upcoming quarters.

The company is focused on advancing its pipeline despite the financial results.

Sarepta Therapeutics Misses on EPS — Stock Down 0.31%

Key numbers

Management commentary

Sarepta Therapeutics, Inc.

More earnings this week

Sarepta Therapeutics Misses on EPS — Stock Down 0.31%

Key numbers

Management commentary